{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-283673","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2024-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.606767+00:00","generated_at":"2026-05-28T23:44:55.259417+00:00","sec_items":["1.01","1.02","2.03","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TScan refinances convertible debt with up to $52.5M term loan from Silicon Valley Bank","bullets":["First tranche of $32.5M drawn at closing; used to retire $17.2M existing convertible debt with K2 HealthVentures plus $2.1M exit fee.","Second tranche of $20M available through June 30, 2026 at SVB's sole discretion.","Interest rate is greater of 7.00% or prime minus 0.75%, capped at 9.75%; maturity September 1, 2029 with interest-only through Sept 2027 if milestones met.","Company expects cash resources to fund operating plan into Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-283673","json":"https://secwatch.observer/filing/0001193125-24-283673.json","markdown":"https://secwatch.observer/filing/0001193125-24-283673.md","text":"https://secwatch.observer/filing/0001193125-24-283673.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000119312524283673/0001193125-24-283673-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000119312524283673/d920508d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T23:44:55.259417+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}